A prospective randomized controlled trial of bone metabolism in patients with charcot foot

BACKGROUND: Diabetic neuroosteoarthropathy (DNOAP, Charcot’s foot) - is a progressive destructive inflammatory disease of the osteoarticular apparatus of the foot, untimely and inadequate treatment of which can lead to the formation of gross deformities. More often, DNOAP is unilateral, bi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ekaterina L. Zaitseva, Alla Y. Tokmakova, Viktor M. Zhilyaev, Natalia M. Malysheva, Natalia I. Sazonova, Gagik R. Galstyan, Aleksandr V. Vorontsov
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2020
Materias:
Acceso en línea:https://doaj.org/article/41a8f461f9764e838d767425160cd468
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:41a8f461f9764e838d767425160cd468
record_format dspace
spelling oai:doaj.org-article:41a8f461f9764e838d767425160cd4682021-11-14T09:00:22ZA prospective randomized controlled trial of bone metabolism in patients with charcot foot2072-03512072-037810.14341/DM11272https://doaj.org/article/41a8f461f9764e838d767425160cd4682020-04-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/11272https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378BACKGROUND: Diabetic neuroosteoarthropathy (DNOAP, Charcot’s foot) - is a progressive destructive inflammatory disease of the osteoarticular apparatus of the foot, untimely and inadequate treatment of which can lead to the formation of gross deformities. More often, DNOAP is unilateral, bilateral lesion is relatively rare. It is not always possible to trace the relationship between the debut of DNOAP with trauma and chronic hyperglycemia. There is data demonstrating the role of individual pro-inflammatory factors in the pathogenesis of DNOAP, however, studies combining the evaluation of various metabolic markers of Charcot’s foot formation are currently extremely poor. AIM: To evaluate the hormonal and metabolic markers of bone formation and resorption in patients with DNOAP and without this diabetic complication. METHODS: A prospective, controlled trial included 70 patients with type 2 diabetes mellitus (37 men and 43 women) who formed 2 groups: group 1 included patients with DNOAP, group 2 was formed by patients with diabetes without foot skeleton damage. All patients underwent a study of 1,25-OH-vitamin D, sclerostin, pro-MMP-1, C-terminal propeptide type 1 collagen (PICP), type 1 collagen, osteocalcin, PTH, 25-OH-vitamin D, beta-cross-slaps. RESULTS: The results of the studies confirmed the presence of vitamin D deficiency in all patients with diabetes mellitus included in the study, revealed the absence of statistically significant differences between the groups in the values of sclerostin, pro-MMP-1; 25-OH-vitamin D, type I collagen, and osteocalcin (p > 0.05). However, significant differences were found in the 1.25-OH vitamin D levels: patients with DNOAP presented the lower rates of 1,25-OH-vitamin D in comparison to control group (p <0.05). Beta-cross and PICP levels were significantly higher in DNOAP patients as well (p <0.05). Those findings show the more severe collagen degradation in patients with DNOAP and can be the genetically predisposed cause of DNOAP development. Though further studies are needed. CONCLUSION: In patients with DNOAP a decrease in 1,25-OH-vitamin D levels was found, as well as the alteration of the synthesis and destruction of collagen (beta-cross-slaps and PICP) compared to patients with diabetes mellitus without osteoarticular disorders.Ekaterina L. ZaitsevaAlla Y. TokmakovaViktor M. ZhilyaevNatalia M. MalyshevaNatalia I. SazonovaGagik R. GalstyanAleksandr V. VorontsovEndocrinology Research Centrearticlediabetes mellituscharcot’s footdnoaposteoarthropathymarkersbone metabolismremodelingNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 23, Iss 1, Pp 12-18 (2020)
institution DOAJ
collection DOAJ
language EN
RU
topic diabetes mellitus
charcot’s foot
dnoap
osteoarthropathy
markers
bone metabolism
remodeling
Nutritional diseases. Deficiency diseases
RC620-627
spellingShingle diabetes mellitus
charcot’s foot
dnoap
osteoarthropathy
markers
bone metabolism
remodeling
Nutritional diseases. Deficiency diseases
RC620-627
Ekaterina L. Zaitseva
Alla Y. Tokmakova
Viktor M. Zhilyaev
Natalia M. Malysheva
Natalia I. Sazonova
Gagik R. Galstyan
Aleksandr V. Vorontsov
A prospective randomized controlled trial of bone metabolism in patients with charcot foot
description BACKGROUND: Diabetic neuroosteoarthropathy (DNOAP, Charcot’s foot) - is a progressive destructive inflammatory disease of the osteoarticular apparatus of the foot, untimely and inadequate treatment of which can lead to the formation of gross deformities. More often, DNOAP is unilateral, bilateral lesion is relatively rare. It is not always possible to trace the relationship between the debut of DNOAP with trauma and chronic hyperglycemia. There is data demonstrating the role of individual pro-inflammatory factors in the pathogenesis of DNOAP, however, studies combining the evaluation of various metabolic markers of Charcot’s foot formation are currently extremely poor. AIM: To evaluate the hormonal and metabolic markers of bone formation and resorption in patients with DNOAP and without this diabetic complication. METHODS: A prospective, controlled trial included 70 patients with type 2 diabetes mellitus (37 men and 43 women) who formed 2 groups: group 1 included patients with DNOAP, group 2 was formed by patients with diabetes without foot skeleton damage. All patients underwent a study of 1,25-OH-vitamin D, sclerostin, pro-MMP-1, C-terminal propeptide type 1 collagen (PICP), type 1 collagen, osteocalcin, PTH, 25-OH-vitamin D, beta-cross-slaps. RESULTS: The results of the studies confirmed the presence of vitamin D deficiency in all patients with diabetes mellitus included in the study, revealed the absence of statistically significant differences between the groups in the values of sclerostin, pro-MMP-1; 25-OH-vitamin D, type I collagen, and osteocalcin (p > 0.05). However, significant differences were found in the 1.25-OH vitamin D levels: patients with DNOAP presented the lower rates of 1,25-OH-vitamin D in comparison to control group (p <0.05). Beta-cross and PICP levels were significantly higher in DNOAP patients as well (p <0.05). Those findings show the more severe collagen degradation in patients with DNOAP and can be the genetically predisposed cause of DNOAP development. Though further studies are needed. CONCLUSION: In patients with DNOAP a decrease in 1,25-OH-vitamin D levels was found, as well as the alteration of the synthesis and destruction of collagen (beta-cross-slaps and PICP) compared to patients with diabetes mellitus without osteoarticular disorders.
format article
author Ekaterina L. Zaitseva
Alla Y. Tokmakova
Viktor M. Zhilyaev
Natalia M. Malysheva
Natalia I. Sazonova
Gagik R. Galstyan
Aleksandr V. Vorontsov
author_facet Ekaterina L. Zaitseva
Alla Y. Tokmakova
Viktor M. Zhilyaev
Natalia M. Malysheva
Natalia I. Sazonova
Gagik R. Galstyan
Aleksandr V. Vorontsov
author_sort Ekaterina L. Zaitseva
title A prospective randomized controlled trial of bone metabolism in patients with charcot foot
title_short A prospective randomized controlled trial of bone metabolism in patients with charcot foot
title_full A prospective randomized controlled trial of bone metabolism in patients with charcot foot
title_fullStr A prospective randomized controlled trial of bone metabolism in patients with charcot foot
title_full_unstemmed A prospective randomized controlled trial of bone metabolism in patients with charcot foot
title_sort prospective randomized controlled trial of bone metabolism in patients with charcot foot
publisher Endocrinology Research Centre
publishDate 2020
url https://doaj.org/article/41a8f461f9764e838d767425160cd468
work_keys_str_mv AT ekaterinalzaitseva aprospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT allaytokmakova aprospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT viktormzhilyaev aprospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT nataliammalysheva aprospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT nataliaisazonova aprospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT gagikrgalstyan aprospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT aleksandrvvorontsov aprospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT ekaterinalzaitseva prospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT allaytokmakova prospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT viktormzhilyaev prospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT nataliammalysheva prospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT nataliaisazonova prospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT gagikrgalstyan prospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
AT aleksandrvvorontsov prospectiverandomizedcontrolledtrialofbonemetabolisminpatientswithcharcotfoot
_version_ 1718429520945479680